ATE420961T1 - Rekombinante anti-tumor rnase - Google Patents

Rekombinante anti-tumor rnase

Info

Publication number
ATE420961T1
ATE420961T1 AT99914174T AT99914174T ATE420961T1 AT E420961 T1 ATE420961 T1 AT E420961T1 AT 99914174 T AT99914174 T AT 99914174T AT 99914174 T AT99914174 T AT 99914174T AT E420961 T1 ATE420961 T1 AT E420961T1
Authority
AT
Austria
Prior art keywords
proteins
recombinant
ribonucleases
active
rnase
Prior art date
Application number
AT99914174T
Other languages
English (en)
Inventor
Susanna Rybak
Dianne Newton
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE420961T1 publication Critical patent/ATE420961T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99914174T 1998-03-27 1999-03-26 Rekombinante anti-tumor rnase ATE420961T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7975198P 1998-03-27 1998-03-27

Publications (1)

Publication Number Publication Date
ATE420961T1 true ATE420961T1 (de) 2009-01-15

Family

ID=22152577

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914174T ATE420961T1 (de) 1998-03-27 1999-03-26 Rekombinante anti-tumor rnase

Country Status (6)

Country Link
EP (1) EP1068332B1 (de)
AT (1) ATE420961T1 (de)
AU (1) AU755147B2 (de)
CA (1) CA2324646A1 (de)
DE (1) DE69940307D1 (de)
WO (1) WO1999050398A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869604B1 (en) 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125771A0 (en) * 1996-02-21 1999-04-11 Us Gov Health & Human Serv Recombinant ribonuclease proteins
US6649392B1 (en) * 1996-04-04 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Mutant form of a cytotoxic ribonucleolytic protein which allows production by recombinant methods
EP0975674B1 (de) * 1997-05-02 2005-08-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen

Also Published As

Publication number Publication date
DE69940307D1 (de) 2009-03-05
EP1068332A2 (de) 2001-01-17
WO1999050398A3 (en) 1999-12-23
AU755147B2 (en) 2002-12-05
AU3207499A (en) 1999-10-18
CA2324646A1 (en) 1999-10-07
EP1068332B1 (de) 2009-01-14
WO1999050398A2 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
EP1200124A4 (de) Immunglobulin fusionsproteine
ZA200200789B (en) Multiple cytokine-antibody complexes.
NZ502392A (en) Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
DE69435049D1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
EP2298805A3 (de) Optimierte FC Varianten und Methoden zu ihrer Herstellung
ATE251448T1 (de) Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
DE59708952D1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
EP1501935A4 (de) Kostengünstige herstellung von peptiden
NO20033673L (no) Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur
DK1214344T3 (da) Dipeptidylpeptidaser
WO2020247388A8 (en) Il-2alpha receptor subunit binding compounds
WO2000048621A3 (en) Methods and compositions for regulating protein-protein interactions
MXPA05003887A (es) Antagonistas il - 15.
MX2023004335A (es) Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas.
ATE420961T1 (de) Rekombinante anti-tumor rnase
AU7216498A (en) Inhibitors of the urokinase receptor
AU703179B2 (en) Recombinant canine gastric lipase and pharmaceutical compositions
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
WO2000068416A3 (de) Methoden zur auffindung von proteasen, die spezifisch membrangebundene substrate spalten
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
GB2360772B (en) Compounds for targeting
WO2002052022A3 (en) Selective cytotoxic fusion proteins
WO2000042063A3 (de) Peptide zur inhibierung von hbv-core-proteinen
WO2002043770A3 (en) Homing peptide multimers, their preparation and uses

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties